STOCK TITAN

Iovance Biotherapeutics (IOVA) DEF 14A Filings

IOVA NASDAQ

Here are the DEF 14A proxy statements from Iovance Biotherapeutics, Inc. (IOVA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IOVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOVA filings page.

Rhea-AI Summary

Iovance Biotherapeutics is asking stockholders to approve seven proposals at its 2026 virtual-only annual meeting on June 10, 2026. Holders of 446,502,396 shares of common stock as of April 15, 2026 can vote online, by phone, mail, or during the webcast.

Stockholders will vote on re-electing six directors, an advisory “say on pay” for named executive officers, and how often to hold future say-on-pay votes. They will also consider ratifying Ernst & Young LLP as auditor for 2026, adding 1,000,000 shares to the 2020 Employee Stock Purchase Plan, increasing authorized common stock from 500,000,000 to 650,000,000 shares, and a potential adjournment to solicit more proxies if Proposal 6 lacks support.